Enzymatic action causes membrane lipid degradation and release of arachidonic acid, which later produces ROS upon metabolism (Gutirrez et al
9.6%).21 A meta-analysis of 16 RCTs of orlistat 120 mg 3 times daily ( n = 10 631 participants) reported a mean placebo-subtracted weight change of 2.9% (95% CI 3.4% to 2.5%) at 1 year.53 The most common adverse effects with orlistat included oily stool, fecal urgency, and spotting, occurring in 15%30% of patients and leading to discontinuation in some cases.53 Further details on efficacy, potential adverse effects, contraindications, and potential medication interactions are available in Appendix 1, and are reviewed in greater detail in the full guideline on the Obesity Canada website.7 Long-term treatment After weight loss with pharmacotherapy Obesity medications are intended as part of a long-term treatment strategy (Table 1, recommendation 4)
The key enzyme of the trans-selenation pathway (cystathionine -lyase) is known to be expressed in the brain (Diwakar and Ravindranath, 2007
and promote angiogenesis the growth of new blood vessels into healing tissue
In the presence of GI AEs, one of the first precautions recommended is to extend the titration period or delay dose escalation until symptoms subside
HDL-C, High density lipoprotein-cholesterol